UnitedHealth price target lowered to $605 from $632 at Stephens

Stephens lowered the firm’s price target on UnitedHealth to $605 from $632 and keeps an Overweight rating on the shares after the company said it sees the high-end of the initial FY25 adjusted EPS framework as likely matching $30.00, versus the Street’s $31.17 consensus, which the firm sees “reflecting prudency around the ongoing reimbursement/utilization headwinds facing the MCO sector.” Noting that UnitedHealth says it hopes to initiate guidance with the capacity to drive positive revisions throughout 2025, the firm says it views UnitedHealth as well-positioned within Medicare Advantage given competitor disruptions.